Media Center

In the media

The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million

Ara

29/12/2020

The Chinese SciClone enters at the biotech Ability Pharma

La Vanguardia

29/12/2020

Ability tests successfully a drug for neuroblastoma

Expansión

17/12/2020

The great leap of a Catalan 'biotech' to cure pancreatic cancer

ARA

09/12/2020

Ability logra financiación de la FDA y abre una ronda en Capital Cell

Expansión

22/10/2020

Ability Pharma capta dos millones de dólares de la FDA para su ensayo clínico de páncreas

Planta Doce

22/10/2020

AbilityPharma capta 5 M€ per a un assaig contra el càncer de pàncreas

ARA

25/03/2020

Ability Pharma receives the acknowledgement from Cerdanyola Empresarial

Parc UAB newsletter

22/11/2019

Ability reinforces the direction and rises 2 million euros from Inveready and Everis

Expansión

13/09/2019

Ability Pharma rises 3.5M€ to finish the clinical trial in cancer

Ara

13/09/2019

A Catalan drug can extend the life expectancy of patients with lung and endometrial cancer

RAC1

06/06/2019

Nine Catalan biotechs among the most promising in Europe

La Vanguardia

28/05/2019

AbilityPharma will start research for cancer in China

El Punt Avui

05/02/2019

The partner of AbilityPharma in China starts clinical trials with the licensed drug

Expansión

04/02/2019

AbilityPharma rises 1.2M euros with the biggest round of Capitall Cell

Ara

10/12/2018

AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA

Expansión

08/11/2018

TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech

Innovaspain

26/09/2018

Cómo facilitar la salida a bolsa de empresas biotecnológicas

Diario Medico

26/09/2018

ABILITY PHARMA COMENÇA LA FASE 2 DEL SEU NOU ANTICANCERIGEN

La Vanguardia

20/09/2018

ABILITYPHARMA ABRE UNA RONDA PARA LUCHAR CONTRA EL CÁNCER

Expansión

13/09/2018

LATEST NEWS

09.09.2024

Press Release

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024

Press Release

AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024

Press Release

AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG